Ishita Drugs & Industries Ltd. (BSE: 524400) is a Ahmedabad, Gujarat-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹22 Cr, it ranks #4,543 by market cap among the 6,137 Indian listed companies on FinBizNet, and #79 of 86 in Medicinal Chemicals and Botanical Products. At ₹70.01 (as of 25 Oct 2026), the share price is 22.9% below its 52-week high of ₹90.85 and 6.1% above its 52-week low of ₹66.00. The share price is down 5.4% over one year and down 5.5% over three months.
| Current Price | ₹70.01 |
|---|---|
| Market Cap | ₹22 Cr |
| BSE Code | 524400 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 28 |
| Return on Equity | 6.96% |
| Return on Assets | 3.03% |
| 52-Week Range | ₹66.00 – ₹90.85 |
| 1-Year Price Change | -5.4% |
| 3-Month Price Change | -5.5% |
| Beta (1Y) | -0.09 |
| Headquarters | Ahmedabad, Gujarat |
| Website | www.ishitadrugs.com |
Ishita Drugs and Industries Limited manufactures and sells active pharma ingredients (APIs), fine chemicals, drug intermediates, and excipients in India and internationally. The company offers APIs, such as sulfa drugs/sulfonamides, vitamins, fluoro quinolones, antibiotics, anthelmintics, iodides and citrates, food additives/excipients, and others. It also provides contract manufacturing services for various drug intermediates, fine chemicals, or specialty chemicals. Ishita Drugs and Industries Limited was incorporated in 1992 and is based in Ahmedabad, India.
1. Pharmaceutical Business-This segment manufactures and markets various active pharma ingredients, drug intermediates, excipients, finished dosage forms, and fine chemicals.
1. Pharmaceutical Business-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Ishita Drugs & Industries Ltd. | ₹22 Cr | 28 | 6.96% | — | -5.4% |
Listed by market capitalisation. Ratios are shown for context only.
Ishita Drugs & Industries Ltd. is trading at ₹70.01, with a market capitalisation of ₹22 Cr.
Ishita Drugs & Industries Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Ishita Drugs & Industries Ltd. has a P/E of 28 and a return on equity of 6.96%.
Ishita Drugs & Industries Ltd. is listed on the BSE under the scrip code 524400.
Ishita Drugs & Industries Ltd.'s share price is down 5.4% over one year and down 5.5% over three months. Its 52-week range is ₹66.00 to ₹90.85.
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.